Skip to main content
Premium Trial:

Request an Annual Quote

'The Difference Between Life and No Life'

Synthetic biology is trucking along, but "more solid science" is needed, Craig Venter tells Bloomberg Businessweek. "I have been sure we're about to solve all the problems, and next year people will say, 'Where is it?' We have not done it yet,'" he adds.

Building a genome is akin to putting Lego blocks together, Bloomberg Businessweek notes. But Venter says that a good design and cheap and fast DNA synthesis is also necessary. "Genome design is going to be a key part of the future. That’s why we need fast, cheap, accurate DNA synthesis so you can make a lot of iterations of something and test them," he says. "The simple test is: Do you get life? We found just from one letter being wrong out of 1.1 million, it made the difference between life and no life."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.